Therapeutic Paradigm for Combination Therapy with Anti-CD19 Antibody and Venetoclax

摘要

The present disclosure provides anti-CD19 antibodies and Venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or bovine lymphocyte lymphoma. Anti-CD19 antibodies, specifically MOR00208, and Venetoclax are non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and / or bovine lymphocyte lymphoma (SLL) according to a specific treatment paradigm for alleviating therapy-associated oncolytic syndrome. To patients suffering from).